These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 22388666)

  • 1. Economic analysis of active surveillance for localized prostate cancer.
    Kim S; Dall'Era MA; Evans CP
    Curr Opin Urol; 2012 May; 22(3):247-53. PubMed ID: 22388666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The economics of active surveillance for prostate cancer.
    Dall'Era MA
    Curr Opin Urol; 2013 May; 23(3):278-82. PubMed ID: 23449496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychological aspects of active surveillance.
    van den Bergh RC; Korfage IJ; Bangma CH
    Curr Opin Urol; 2012 May; 22(3):237-42. PubMed ID: 22357407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Active surveillance: the Canadian experience.
    Klotz L
    Curr Opin Urol; 2012 May; 22(3):222-30. PubMed ID: 22453335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MRI and surveillance.
    Ouzzane A; Puech P; Villers A
    Curr Opin Urol; 2012 May; 22(3):231-6. PubMed ID: 22388665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Prostate cancer Research International: Active Surveillance study.
    Bangma CH; Bul M; Roobol M
    Curr Opin Urol; 2012 May; 22(3):216-21. PubMed ID: 22453333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of 5-alpha-reductase inhibitors in active surveillance.
    Margel D; Fleshner N
    Curr Opin Urol; 2012 May; 22(3):243-6. PubMed ID: 22472511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer.
    Laviana AA; Ilg AM; Veruttipong D; Tan HJ; Burke MA; Niedzwiecki DR; Kupelian PA; King CR; Steinberg ML; Kundavaram CR; Kamrava M; Kaplan AL; Moriarity AK; Hsu W; Margolis DJ; Hu JC; Saigal CS
    Cancer; 2016 Feb; 122(3):447-55. PubMed ID: 26524087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost comparison between watchful waiting with active surveillance and active treatment of clinically localized prostate cancer.
    Corcoran AT; Peele PB; Benoit RM
    Urology; 2010 Sep; 76(3):703-7. PubMed ID: 20381846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conventional treatments of localized prostate cancer.
    Zerbib M; Zelefsky MJ; Higano CS; Carroll PR
    Urology; 2008 Dec; 72(6 Suppl):S25-35. PubMed ID: 19095125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active surveillance: oncologic outcome.
    Venderbos LD; Bokhorst LP; Bangma CH; Roobol MJ
    Curr Opin Urol; 2013 May; 23(3):268-72. PubMed ID: 23425994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer.
    Aizer AA; Paly JJ; Zietman AL; Nguyen PL; Beard CJ; Rao SK; Kaplan ID; Niemierko A; Hirsch MS; Wu CL; Olumi AF; Michaelson MD; D'Amico AV; Efstathiou JA
    J Clin Oncol; 2012 Sep; 30(25):3071-6. PubMed ID: 22851571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Further support for active surveillance in the management of low-volume, low-grade prostate cancer.
    Albertsen P
    Eur Urol; 2010 Dec; 58(6):836-7. PubMed ID: 20851512
    [No Abstract]   [Full Text] [Related]  

  • 14. Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment.
    Soloway MS; Soloway CT; Eldefrawy A; Acosta K; Kava B; Manoharan M
    Eur Urol; 2010 Dec; 58(6):831-5. PubMed ID: 20800964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer overdiagnosis and overtreatment.
    Klotz L
    Curr Opin Urol; 2012 May; 22(3):203-9. PubMed ID: 22472510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Economic features of active surveillance].
    Huguet J; Musquera M; Ribal MJ; Alcaraz A
    Arch Esp Urol; 2014 Jun; 67(5):509-13. PubMed ID: 24914850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer.
    Sathianathen NJ; Konety BR; Alarid-Escudero F; Lawrentschuk N; Bolton DM; Kuntz KM
    Eur Urol; 2019 Jun; 75(6):910-917. PubMed ID: 30425010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating the healthcare costs of treating prostate cancer in Australia: A Markov modelling analysis.
    Gordon LG; Tuffaha HW; James R; Keller AT; Lowe A; Scuffham PA; Gardiner RA
    Urol Oncol; 2018 Mar; 36(3):91.e7-91.e15. PubMed ID: 29169847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing localized prostate cancer by radical prostatectomy or watchful waiting: Cost analysis of a randomized trial (SPCG-4).
    Andersson SO; Andrén O; Lyth J; Stark JR; Henriksson M; Adami HO; Carlsson P; Johansson JE
    Scand J Urol Nephrol; 2011 Apr; 45(3):177-83. PubMed ID: 21265595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active surveillance vs. treatment for low-risk prostate cancer: a cost comparison.
    Eldefrawy A; Katkoori D; Abramowitz M; Soloway MS; Manoharan M
    Urol Oncol; 2013 Jul; 31(5):576-80. PubMed ID: 21616691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.